These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8646989)

  • 1. [The treatment of carcinoid of the small intestine with octreotide and alpha-interferon. A call for participation in a randomized study].
    Ahrén B
    Dtsch Med Wochenschr; 1996 May; 121(22):744-5. PubMed ID: 8646989
    [No Abstract]   [Full Text] [Related]  

  • 2. [New medical therapy of neuroendocrine gastrointestinal tumors].
    Eriksson B; Janson ET; Skogseid B; Oberg K
    Lakartidningen; 1990 Aug; 87(35):2668-72. PubMed ID: 2214974
    [No Abstract]   [Full Text] [Related]  

  • 3. [Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors].
    Bläker M; de Weerth A
    Z Gastroenterol; 2006 Sep; 44(9):1003-4. PubMed ID: 16981075
    [No Abstract]   [Full Text] [Related]  

  • 4. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours.
    Kölby L; Persson G; Franzén S; Ahrén B
    Br J Surg; 2003 Jun; 90(6):687-93. PubMed ID: 12808615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comments on "Clinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients".
    Schran HF; Hager DF
    Pancreas; 2008 Oct; 37(3):334-5; author reply 336-7. PubMed ID: 18815560
    [No Abstract]   [Full Text] [Related]  

  • 6. Is it time to widen the use of somatostatin analogs in neuroendocrine tumors?
    Oberg KE
    J Clin Oncol; 2009 Oct; 27(28):4635-6. PubMed ID: 19704053
    [No Abstract]   [Full Text] [Related]  

  • 7. Levels of angiogenic peptides in sera from patients with carcinoid tumours during alpha-interferon treatment.
    Nilsson A; Janson ET; Eriksson B; Larsson A
    Anticancer Res; 2001; 21(6A):4087-90. PubMed ID: 11911297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Carcinoid tumors].
    Tóth M; Prónai L; Németh AM; Tulassay Z
    Orv Hetil; 2002 May; 143(19 Suppl):1087-92. PubMed ID: 12063867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors.
    Frank M; Klose KJ; Wied M; Ishaque N; Schade-Brittinger C; Arnold R
    Am J Gastroenterol; 1999 May; 94(5):1381-7. PubMed ID: 10235222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient symptomatic control of carcinoid tumors with somatostatin in patients with disease progression under alpha-interferon therapy.
    Boehme MW; Schmidt-Gayk H; Bihl H; Eisenhut M; Herfarth CH; Kommere B; Raeth U
    Hepatogastroenterology; 1995; 42(6):1053-61. PubMed ID: 8847018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum chromogranin A reflects regression of metastatic carcinoid during prolonged octreotide treatment.
    Pregun I; Gergics P; Dabasi G; Igaz P; Racz K; Tulassay Z
    Eur J Gastroenterol Hepatol; 2009 Apr; 21(4):476-7. PubMed ID: 19382304
    [No Abstract]   [Full Text] [Related]  

  • 12. Carcinoid tumors of the gastrointestinal tract. A review and the Duke University institutional overview.
    Onaitis M; White R; Tyler D
    Minerva Chir; 2003 Feb; 58(1):1-8. PubMed ID: 12692491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carcinoid tumor and intravenous octreotide infusion during labor and delivery.
    Le BT; Bharadwaj S; Malinow AM
    Int J Obstet Anesth; 2009 Apr; 18(2):182-5. PubMed ID: 19200714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA approves marketing of octreotide.
    Clin Pharm; 1989 Jan; 8(1):4. PubMed ID: 2912662
    [No Abstract]   [Full Text] [Related]  

  • 15. An overview on the management of carcinoid tumors.
    Napolitano G; Bucci I; Lio S; Giuliani C; Minnucci A; Monaco F
    J Nucl Biol Med (1991); 1991; 35(4):337-40. PubMed ID: 1823852
    [No Abstract]   [Full Text] [Related]  

  • 16. [Individual therapeutic procedure in metastatic carcinoid of the small intestine].
    Barthel A; Leonhardt U; Stöckmann F; Ramadori G
    Leber Magen Darm; 1996 May; 26(3):164, 167-9. PubMed ID: 8709831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A therapeutic study of hepatocellular carcinoma using octreotide (HECTOR). Hepatocellular Carcinoma: Treatment with Octreotide].
    Allgaier HP; Becker G; Blum HE
    Dtsch Med Wochenschr; 2000 Mar; 125(11):320. PubMed ID: 10761474
    [No Abstract]   [Full Text] [Related]  

  • 18. Octreotide LAR in carcinoid: how to dose?
    Yao JC; Kvols LK
    Pancreas; 2008 Oct; 37(3):337-8; author reply 338-9. PubMed ID: 18815562
    [No Abstract]   [Full Text] [Related]  

  • 19. Transmembrane protein tyrosine phosphatase IA-2 (ICA512) is expressed in human midgut carcinoids but is not detectable in normal enterochromaffin cells.
    Cunningham JL; Lopez-Egido JR; Janson ET; Eriksson B; Oberg K; Gobl AE
    J Endocrinol; 2000 Mar; 164(3):315-22. PubMed ID: 10694371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hereditary neuroendocrine gastroenteropancreatic tumors and multiple endocrine neoplasia type 1].
    Scherübl H; Schaaf L; Raue F; Faiss S; Zeitz M
    Dtsch Med Wochenschr; 2004 Mar; 129(13):689-92. PubMed ID: 15026965
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.